Curio Digital Therapeutics Inc., a New Jersey-based innovative US company treating postpartum depression (PPD) and other underserved women’s mental health conditions, raised a double digit funding round.
Backers included RYSE Asset Management (from its Special Opportunities Fund), ONCE, Bridge Point Capital, and Avestria.
The company intends to use the funds for the continued commercialization with health plans and insurers in the US, UK and India.
Led by Shailja Dixit, MD, MPH, MS, CEO & Founder, Curio Digital Therapeutics develops digital therapeutics solutions and interventions across the behavioral health continuum for women throughout the cycle of life by leveraging proprietary algorithms, clinically validated screening tools, and personalized digital behavioral interventions. The company’s MamaLift Plus is a prescription-only digital therapeutic intended to provide neurobehavioral interventions to patients 22 years of age and older, as an adjunct to clinician-managed outpatient care. Its AI-driven predictive algorithm, Curio-I, identifies and risk stratifies women who would go on to develop common behavioral health conditions.
The company has received FDA approval for its lead product MamaLift Plus.
Curio is currently working with health plans, insurers and corporate employee benefit plans in the US and India. They also work at a strategic level with pharma companies and others who seek to engage with Curio’s data and underlying connected care platform which spans post-natal depression, fertility and menopause.
FinSMEs
28/08/2024